Virtus KAR Health Sciences Fund A (RAGHX)
29.88
-0.07
(-0.23%)
USD |
Dec 30 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.40% | 104.50M | 0.83% | 8.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -23.42M | 8.10% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation by investing at least 65% of its assets in healthcare sector equity securities. Under normal market conditions, the fund will invest at least 65% of its assets will be invested in companies located in at least three different countries, including possibly the United States. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Virtus |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
53
-129.73M
Peer Group Low
1.550B
Peer Group High
1 Year
% Rank:
41
-23.42M
-3.013B
Peer Group Low
514.53M
Peer Group High
3 Months
% Rank:
52
-537.77M
Peer Group Low
1.698B
Peer Group High
3 Years
% Rank:
41
-8.541B
Peer Group Low
312.13M
Peer Group High
6 Months
% Rank:
45
-1.345B
Peer Group Low
1.449B
Peer Group High
5 Years
% Rank:
45
-7.624B
Peer Group Low
2.983B
Peer Group High
YTD
% Rank:
41
-2.538B
Peer Group Low
561.96M
Peer Group High
10 Years
% Rank:
44
-13.08B
Peer Group Low
5.532B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 31, 2025.
*Indicates data for the year is incomplete.
Asset Allocation
As of September 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.00% |
| Stock | 98.48% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 1.52% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 13.63% | 1075.02 | -0.44% |
| AbbVie, Inc. | 6.32% | 228.50 | -0.54% |
| IDEXX Laboratories, Inc. | 6.22% | 676.60 | -0.84% |
| McKesson Corp. | 4.85% | 820.43 | -0.83% |
| Intuitive Surgical, Inc. | 4.61% | 566.56 | -1.06% |
| West Pharmaceutical Services, Inc. | 4.54% | 275.22 | -0.60% |
| Vertex Pharmaceuticals, Inc. | 4.36% | 453.38 | -0.08% |
| Mettler-Toledo International, Inc. | 4.01% | 1394.08 | -1.43% |
| UnitedHealth Group, Inc. | 4.00% | 330.24 | -0.58% |
| The Cooper Cos., Inc. | 3.83% | 81.96 | -0.62% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 0.80% |
| Administration Fee | 131.9K% |
| Maximum Front Load | 5.50% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2500.00 None |
| Minimum Subsequent Investment | 100.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation by investing at least 65% of its assets in healthcare sector equity securities. Under normal market conditions, the fund will invest at least 65% of its assets will be invested in companies located in at least three different countries, including possibly the United States. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Virtus |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (12-29-25) | 0.12% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 25 |
| Stock | |
| Weighted Average PE Ratio | 39.65 |
| Weighted Average Price to Sales Ratio | 7.268 |
| Weighted Average Price to Book Ratio | 11.83 |
| Weighted Median ROE | 39.68% |
| Weighted Median ROA | 10.89% |
| ROI (TTM) | 16.39% |
| Return on Investment (TTM) | 16.39% |
| Earning Yield | 0.0312 |
| LT Debt / Shareholders Equity | 2.368 |
| Number of Equity Holdings | 24 |
As of September 30, 2025
Growth Metrics
| EPS Growth (1Y) | 24.29% |
| EPS Growth (3Y) | 10.53% |
| EPS Growth (5Y) | 15.46% |
| Sales Growth (1Y) | 11.77% |
| Sales Growth (3Y) | 9.40% |
| Sales Growth (5Y) | 12.34% |
| Sales per Share Growth (1Y) | 12.49% |
| Sales per Share Growth (3Y) | 10.25% |
| Operating Cash Flow - Growth Rate (3Y) | 5.50% |
As of September 30, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:RAGHX", "name") |
| Broad Asset Class: =YCI("M:RAGHX", "broad_asset_class") |
| Broad Category: =YCI("M:RAGHX", "broad_category_group") |
| Prospectus Objective: =YCI("M:RAGHX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |